Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.

Korea: A recent study published in the Radiology Journal has highlighted the significant role of obesity and skeletal muscle ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

The five-year relative survival rate of small cell lung cancer—the odds that a cancer patient will live another five years compared to a non-patient—ranges from 7% to 30% depending on the ...